BioSpace News Archive

Immune Pharmaceuticals, Inc. Completes Underwriter’s Exercise Of Partial Over-Allotment Option

December 1, 2014
·
6 min read
FDA

Bayer Receives Health Canada Approval for Eylea For Two Additional Indications

December 1, 2014
·
9 min read
Business

BioClinica, Inc. Names Dr. John Hubbard Chief Executive Officer

December 1, 2014
·
3 min read
BioMidwest

Veniti Announces First U.S. Patients Enrolled In VIRTUS Trial

December 1, 2014
·
2 min read
Policy

Regeneron Release: EYLEA (aflibercept) Injection Accepted For Priority Review By FDA For Diabetic Retinopathy In Patients With Diabetic Macular Edema

December 1, 2014
·
9 min read
Drug Development

Otonomy, Inc. Achieves Patient Enrollment Target In Phase 2b Clinical Trial Of OTO-104 In Meniere’s Disease

December 1, 2014
·
6 min read
BioForest

Galena Biopharma To Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data At The 56th American Society of Hematology Annual Meeting & Exposition

December 1, 2014
·
3 min read
Drug Development

OncoMed Pharmaceuticals, Inc. Begins Patient Dosing In Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer

December 1, 2014
·
9 min read
Drug Development

Karyopharm Therapeutics Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC)

December 1, 2014
·
5 min read
Policy

Momenta Pharmaceuticals, Inc. Announces Acceptance Of A Clinical Trial Application In Europe For M923, A Biosimilar Version Of Humira

December 1, 2014
·
4 min read